Literature DB >> 23352833

Autocrine CCL2, CXCL4, CXCL9 and CXCL10 signal in retinal endothelial cells and are enhanced in diabetic retinopathy.

M I Nawaz1, K Van Raemdonck, G Mohammad, D Kangave, J Van Damme, A M Abu El-Asrar, S Struyf.   

Abstract

This study aimed at examining the presence and role of chemokines (angiogenic CCL2/MCP-1 and angiostatic CXCL4/PF-4, CXCL9/Mig, CXCL10/IP-10) in proliferative diabetic retinopathy (PDR). Regulated chemokine production in human retinal microvascular cells (HRMEC) and chemokine levels in vitreous samples from 40 PDR and 29 non-diabetic patients were analyzed. MCP-1, PF-4, Mig, IP-10 and VEGF levels in vitreous fluid from PDR patients were significantly higher than in controls. Except for IP-10, cytokine levels were significantly higher in PDR with active neovascularization and PDR without traction retinal detachment (TRD) than those in inactive PDR, PDR with TRD and control subjects. Exploratory regression analysis identified associations between higher levels of IP-10 and inactive PDR and PDR with TRD. VEGF levels correlated positively with MCP-1 and IP-10. Significant positive correlations were observed between MCP-1 and IP-10 levels. In line with these clinical findings Western blot analysis revealed increased PF-4 expression in diabetic rat retinas. HRMEC produced MCP-1, Mig and IP-10 after stimulation with IFN-γ, IL-1β or lipopolysaccharide. IFN-γ synergistically enhanced Mig and IP-10 production in response to IL-1β or lipopolysaccharide. MCP-1 was produced by HRMEC in response to VEGF treatment and activated HRMEC via the ERK and Akt/PKB pathway. On the other hand, phosphorylation of ERK induced by VEGF and MCP-1 was inhibited by PF-4, Mig and IP-10. In accordance with inhibition of angiogenic signal transduction pathways, PF-4 inhibited in vitro migration of HRMEC. Thus, regulatory roles for chemokines in PDR were demonstrated. In particular, IP-10 might be associated with the resolution of active PDR and the development of TRD.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23352833     DOI: 10.1016/j.exer.2013.01.008

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  38 in total

1.  Inflammatory cytokine-specific alterations in retinal endothelial cell function.

Authors:  Tammy L Palenski; Christine M Sorenson; Nader Sheibani
Journal:  Microvasc Res       Date:  2013-06-24       Impact factor: 3.514

Review 2.  Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment.

Authors:  Steven F Abcouwer; Thomas W Gardner
Journal:  Ann N Y Acad Sci       Date:  2014-03-27       Impact factor: 5.691

3.  Identification of a novel neurotrophic factor from primary retinal Müller cells using stable isotope labeling by amino acids in cell culture (SILAC).

Authors:  Christine von Toerne; Jacob Menzler; Alice Ly; Nicole Senninger; Marius Ueffing; Stefanie M Hauck
Journal:  Mol Cell Proteomics       Date:  2014-06-12       Impact factor: 5.911

4.  Angiogenic Factors and Cytokines in Diabetic Retinopathy.

Authors:  Steven F Abcouwer
Journal:  J Clin Cell Immunol       Date:  2013

5.  The Chemokine Platelet Factor-4 Variant (PF-4var)/CXCL4L1 Inhibits Diabetes-Induced Blood-Retinal Barrier Breakdown.

Authors:  Ahmed M Abu El-Asrar; Ghulam Mohammad; Mohd Imtiaz Nawaz; Mohammed Abdelsaid; Mohammad Mairaj Siddiquei; Kaiser Alam; Kathleen Van den Eynde; Gert De Hertogh; Ghislain Opdenakker; Mohamed Al-Shabrawey; Jo Van Damme; Sofie Struyf
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-02-24       Impact factor: 4.799

6.  Elevation of the vitreous body concentrations of oxidative stress-responsive apoptosis-inducing protein (ORAIP) in proliferative diabetic retinopathy.

Authors:  Yuta Suzuki; Takako Yao; Ko Okumura; Yoshinori Seko; Shigehiko Kitano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-05-06       Impact factor: 3.117

Review 7.  Changes in aqueous and vitreous inflammatory cytokine levels in proliferative diabetic retinopathy: a systematic review and meta-analysis.

Authors:  Ryan H Mason; Samuel A Minaker; Gabriela Lahaie Luna; Priya Bapat; Armin Farahvash; Anubhav Garg; Nishaant Bhambra; Rajeev H Muni
Journal:  Eye (Lond)       Date:  2022-06-07       Impact factor: 4.456

Review 8.  Models of retinal diseases and their applicability in drug discovery.

Authors:  Goldis Malek; Julia Busik; Maria B Grant; Mayur Choudhary
Journal:  Expert Opin Drug Discov       Date:  2018-01-30       Impact factor: 6.098

9.  Nuclear receptor RORα regulates pathologic retinal angiogenesis by modulating SOCS3-dependent inflammation.

Authors:  Ye Sun; Chi-Hsiu Liu; John Paul SanGiovanni; Lucy P Evans; Katherine T Tian; Bing Zhang; Andreas Stahl; William T Pu; Theodore M Kamenecka; Laura A Solt; Jing Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-04       Impact factor: 11.205

10.  Neurotrophins and neurotrophin receptors in proliferative diabetic retinopathy.

Authors:  Ahmed M Abu El-Asrar; Ghulam Mohammad; Gert De Hertogh; Mohd Imtiaz Nawaz; Kathleen Van Den Eynde; Mohammad Mairaj Siddiquei; Sofie Struyf; Ghislain Opdenakker; Karel Geboes
Journal:  PLoS One       Date:  2013-06-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.